Marine De Fages News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Marine de fages. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Marine De Fages Today - Breaking & Trending Today

Aelis Farma: Ordinary General Meeting of June 28, 2022: Availability of Preparatory Documents and Participation and Voting Procedures

Regulatory News: Aelis Farma (ISIN code: FR0014007ZB4 ticker: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases (the Company »), ....

United States , Nicolas Merigeau , Vincenzo Piazza , Inserm Magendie Neurocentre , Daelis Farma , Albert Marquet , Inserm Transfert Initiative , Centre Broca Nouvelle Aquitaine , Neurology Of The French Academy Sciences , Regulatory News , Ordinary General Meeting , General Meeting , Investors General , Commercial Code , Signaling Specific , Pier Vincenzo Piazza , Grand Prix , French Academy , Nouvelle Aquitaine Region , Euronext Paris , Marine De Fages ,

AELIS FARMA: Aelis Farma: Publication of the 2021 Annual Financial Report

Regulatory News: Aelis Farma (ISIN code: FR0014007ZB4 ticker: AELIS) (Paris: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases (the ....

United States , France General , Nicolas Merigeau , Vincenzo Piazza , Inserm Magendie Neurocentre , Daelis Farma , Inserm Transfert Initiative , French Financial Markets Authority Autorit , Neurology Of The French Academy Sciences , Regulatory News , French Financial Markets Authority , Signaling Specific , Pier Vincenzo Piazza , Grand Prix , French Academy , Nouvelle Aquitaine Region , Euronext Paris , Marine De Fages ,

ODDO BHF Initiates the Coverage of Aelis Farma With a Buy Recommendation

Regulatory News: Aelis Farma (ISIN code: FR0014007ZB4 ticker: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases (the Company »), ....

United States , Nicolas Merigeau , Vincenzo Piazza , Inserm Magendie Neurocentre , Daelis Farma , Inserm Transfert Initiative , Neurology Of The French Academy Sciences , Regulatory News , General Meeting , Signaling Specific , Pier Vincenzo Piazza , Grand Prix , French Academy , Nouvelle Aquitaine Region , Marine De Fages ,

Aelis Farma, a biopharmaceutical company developing a new generation of drugs for brain diseases, announces the success of its initial public offering and raises approximately €25 million on Euronext Paris

Capital increase of approximately €25 million, i.e. 100% of the initial objective, despite high market volatility Size of the transaction which may be increased to approximately €25.55 million ....

United States , United Kingdom , Bpifrance Financement , Kostenloser Wertpapierhandel , Nicolas Merigeau , Vincenzo Piazza , Inserm Magendie Neurocentre , Daelis Farma , Indivior United Kingdom Ltd , Inserm Transfert Initiative , European Parliament , United Kingdom Financial Conduct Authority , Neurology Of The French Academy Sciences , Financial Services , European Union Withdrawal , Commission Delegated Directive , Innovative Company , Over Allotment Option , Euronext Paris , Signaling Specific , Pier Vincenzo Piazza , Global Offering , Euro Micro Caps , Madison Avenue Partners , Two Seas Capital , New Shares ,

Aelis Farma, a Biopharmaceutical Company Developing a New Generation of Drugs for Brain Diseases, Launches Its Initial Public Offering on the Regulated Market of Euronext Paris

Capital increase of €25 million, which may be increased to a maximum of approximately €33 million in the event the Extension Clause and the Over-Allotment Option are fully exercised Irrevocable ....

United States , France General , United Kingdom , South Africa , Comunidad Autonoma De Cataluna , Kostenloser Wertpapierhandel , Nicolas Merigeau , Vincenzo Piazza , Inserm Magendie Neurocentre , Daelis Farma , Frances Levin , European Council , National Institute Of Health , United Kingdom Financial Conduct Authority , Neurology Of The French Academy Sciences , European Union Withdrawal , European Union , Commission Delegated Directive , Bpifrance Innovative Company , Nouvelle Aquitaine Co , Innovative Company , European Union Horizon , Inserm Transfert Initiative , European Parliament , Garnier Co , Financial Services ,